Standout Papers
- Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants (2020)
- Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials (2023)
Immediate Impact
1 by Nobel laureates 10 from Science/Nature 55 standout
Citing Papers
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus
2025 Standout
Works of Therese Takas being referenced
Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses
2017
An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Therese Takas | 996 | 470 | 105 | 374 | 21 | 1.1k | |
| Debra Tristram | 1074 | 591 | 114 | 368 | 25 | 1.3k | |
| Vivek Shinde | 1009 | 286 | 116 | 405 | 31 | 1.2k | |
| Franco M. Piazza | 836 | 461 | 143 | 203 | 12 | 1.2k | |
| David Prince | 589 | 174 | 56 | 402 | 28 | 925 | |
| R. Mitchell | 786 | 293 | 156 | 410 | 40 | 1.2k | |
| David Wong | 831 | 350 | 163 | 243 | 25 | 1.2k | |
| Micki Hultquist | 855 | 214 | 356 | 292 | 13 | 1.2k | |
| Xionghua Wu | 772 | 273 | 139 | 246 | 26 | 1.1k | |
| Charles Sande | 942 | 508 | 143 | 367 | 31 | 1.2k | |
| Selina Tsim | 346 | 686 | 47 | 243 | 32 | 1.2k |
All Works
Loading papers...